Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
TLK286.2018
NCT00051948
January 2003
January 2005
Name | Location |
---|---|
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Midwest Cancer Research Group, Inc. | Skokie, Illinois 60077 |
Dana Farber Cancer Institute | Boston, Massachusetts 02115 |
M.D. Anderson Cancer Center | Houston, Texas 77030 |
Santa Monica Hematology/Oncology Consultants | Santa Monica, California 90404 |